Results 201 to 210 of about 40,970 (289)

Oligodendrocyte: Development, Plasticity, Biological Functions, Diseases, and Therapeutic Targets

MedComm, Volume 7, Issue 2, February 2026.
The oligodendrocyte lineage and its roles in development, plasticity, and CNS homeostasis have been shown to have the potential to treat neurological diseases. However, the main obstacles to clinical translation, particularly in terms of BBB challenges and precise delivery.
Qiong Xiang, Ruo‐Lan Shi, You‐Xia Huang, Li‐Ni Liu, Jia‐Sheng Tao, Xian‐Hui Li, Xiao‐Da Li   +6 more
wiley   +1 more source

Mutational dissection of HCMV gB and gH cytoplasmic tails highlights conserved and divergent features of fusion regulation. [PDF]

mBio
Lee C, DiBella HK, Heldwein EE.
europepmc   +1 more source

Molecular biology of platelet membrane glycoproteins.

Blood & Vessel, 1989
Makoto HANDA, Yasuo IKEDA, Yoko KAWAI, Mihoko YAMAMOTO, Kiyoaki WATANABE   +4 more
openaire   +2 more sources

Development of a Pregnancy‐Specific Physiologically Based Pharmacokinetics (PBPK) Model for Aspirin

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Aspirin is one of the most commonly used medications in pregnancy, particularly for the prevention of hypertensive disorders. Despite aspirin's widespread use in pregnancy for preeclampsia prevention, its pharmacokinetics (PK) across all trimesters remain poorly characterized, complicating optimal dosing recommendations. To develop a pregnancy‐
Ana Collins‐Smith, Ananth Kumar Kammala, Mitch A. Phelps, Xiao Ming Wang, Ramkumar Menon, Maged M. Costantine   +5 more
wiley   +1 more source

Zyxin restricts viral fusion and entry across multiple virus families. [PDF]

J Virol
Fan Q, Quan J, Smith GA, Longnecker R.
europepmc   +1 more source

Advances in the Development of Lipid Nanoparticles for mRNA Delivery

Small Structures, Volume 7, Issue 2, February 2026.
This review provides an integrated overview of mRNA–lipid nanoparticle (LNP) design, including lipid composition, scalable manufacturing, and structure–activity relationships. We highlight strategies for targeted delivery, physicochemical tuning, and high‐throughput screening such as DNA barcoding.
Xing Wang, Letao Xu, Zhenwei Lan, Yue Hui, Yun Liu, Guangze Yang, Chun‐Xia Zhao   +6 more
wiley   +1 more source

Ceftriaxone-Induced Thrombocytopenia: A Case Report on a Rare Medical Condition. [PDF]

Cureus
Aryal B, Simmons A, Ekkurthi G, Panthi B, Pena-Vizcarra OR.   +4 more
europepmc   +1 more source

Prognostic Impact of DPP4 Inhibitors on Systemic Drug Therapy for Advanced Kidney Cancer Patients

Cancer Science, Volume 117, Issue 2, Page 468-475, February 2026.
Treatment with DPP4 inhibitors was identified as a favorable prognostic factor in patients with advanced RCC. A more substantial degree of tumor shrinkage was observed in the subgroup of patients who received tyrosine kinase inhibitors or immune checkpoint inhibitors as first‐line therapy.
Shuhei Kamada, Sachi Kitayama, Ryosuke Yamase, Kazuhiro Ikeda, Wataru Sato, Tomokazu Sazuka, Hideki Takeshita, Shinichi Sakamoto, Akihiro Yano, Kuniko Horie, Tomohiko Ichikawa, Satoru Kawakami, Satoshi Inoue   +12 more
wiley   +1 more source

MicroRNA-223-3p is a determinant of platelet procoagulant activity. [PDF]

Blood Adv
Charlon-Gay J, Nolli S, Dunoyer-Geindre S, Ciepla P, Reny JL, Fontana P.   +5 more
europepmc   +1 more source

Prevention of In‐Stent Restenosis After PCI by Saponin Natural Products: Inhibition of Platelet Activation

Journal of Cellular and Molecular Medicine, Volume 30, Issue 3, February 2026.
ABSTRACT Percutaneous coronary intervention (PCI) enables coronary revascularisation and restores haemodynamic stability but also carries risks of delayed complications including in‐stent restenosis (ISR), a chronic progressive disease with endovascular damage after PCI, which compromises the long‐term efficacy of PCI.
Xueli Lei, Chunlei Lv, Yu Zhang, Zhiyu Li, Hao Shen, Li Zhu   +5 more
wiley   +1 more source